NOVAVAX INC Shareholders' Equity
NOVAVAX INC (NVAX) had Shareholders' Equity of -$190.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent -$190.71M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$144.76M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$127.75M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$156.67M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$190.71M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$144.76M 10-Q · filed 2026-08-06 |
| 2025-12-31 | -$127.75M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$156.67M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $37.63M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$75.64M 10-Q · filed 2026-08-06 |
| 2024-12-31 | -$623.84M 10-Q · filed 2026-08-06 |
| 2024-09-30 | -$526.44M 10-Q · filed 2025-11-06 |
| 2024-06-30 | -$431.71M 10-Q · filed 2025-11-06 |
| 2024-03-31 | -$867.08M 10-Q · filed 2025-08-06 |
| 2023-12-31 | -$716.93M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$678.35M 10-Q · filed 2024-11-12 |
| 2023-06-30 | -$754.52M 10-Q · filed 2024-11-12 |
| 2023-03-31 | -$895.58M 10-Q · filed 2024-08-08 |
| 2022-12-31 | -$634.08M 10-K · filed 2026-02-26 |
| 2022-09-30 | -$565.99M 10-Q · filed 2023-11-09 |
| 2022-06-30 | -$416.95M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $65.32M 10-Q · filed 2023-08-08 |
| 2021-12-31 | -$351.67M 10-K · filed 2025-02-27 |
| 2021-09-30 | $461.34M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $745.56M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $1.04B 10-Q · filed 2022-08-09 |
| 2020-12-31 | $627.21M 10-K · filed 2024-02-28 |
| 2020-09-30 | $106.44M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $184.53M 10-Q · filed 2021-11-05 |
| 2020-03-31 | -$23.97M 10-Q · filed 2021-08-05 |
| 2019-12-31 | -$186.02M 10-K · filed 2023-02-28 |
| 2019-09-30 | -$189.84M 10-Q · filed 2020-11-10 |
| 2019-06-30 | -$185.49M 10-Q · filed 2020-11-10 |
| 2019-03-31 | -$150.58M 10-Q · filed 2020-08-10 |
| 2018-12-31 | -$167.94M 10-K · filed 2022-03-01 |
| 2018-09-30 | -$126.68M 10-Q · filed 2019-11-07 |
| 2018-06-30 | -$87.71M 10-Q · filed 2019-11-07 |
| 2018-03-31 | -$99.37M 10-Q · filed 2019-08-07 |
| 2017-12-31 | -$101.73M 10-K · filed 2021-03-01 |
| 2017-09-30 | -$74.15M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$59.06M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$29.10M 10-Q · filed 2017-05-08 |
| 2016-12-31 | -$5.55M 10-K · filed 2020-03-11 |
| 2016-09-30 | $49.78M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $110.12M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $185.43M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $292.67M 10-K · filed 2019-03-18 |
| 2015-09-30 | $367.02M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $387.60M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $399.71M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $229.62M 10-K · filed 2018-03-14 |
| 2014-09-30 | $261.65M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $281.73M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $191.06M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $203.23M 10-K · filed 2017-02-27 |
| 2013-09-30 | $216.57M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $69.23M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $77.57M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $80.24M 10-K · filed 2016-02-29 |
| 2012-09-30 | $61.38M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $61.08M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $54.32M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $53.85M 10-K · filed 2015-02-27 |
| 2011-09-30 | $54.60M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $56.27M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $59.05M 10-K · filed 2014-03-12 |
| 2009-12-31 | $69.95M 10-K · filed 2013-03-12 |
| 2008-12-31 | $42.95M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |